[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354758-105":59,"doc-detail-354758-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","early-risk-prediction-in-endometrial-cancer-using-biomarker-and-machine-learning-models-a-systematic-review-and-meta-analysis-protocol","Early risk prediction in endometrial cancer - using biomarker and machine learning models - a systematic review and meta-analysis protocol","","Endometrial cancer is a leading and growing gynaecological malignancy, making accurate early prognostic assessment crucial for personalized treatment and improved long-term outcomes. Traditional clinicopathological approaches such as FIGO staging and tumor grade have limitations in detecting early recurrence risk. This protocol evaluates whether biomarker-based signatures and machine-learning guided risk models, including radiomics and multi-omics, improve early risk prediction versus conventional methods. The review outlines eligibility criteria, outcomes, bias assessment, and planned meta-analyses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/early-risk-prediction-in-endometrial-cancer-using-biomarker-and-machine-learning-models-a-systematic-review-and-meta-analysis-protocol/354758/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/early-risk-prediction-in-endometrial-cancer-using-biomarker-and-machine-learning-models-a-systematic-review-and-meta-analysis-protocol/354758.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the review protocol address in endometrial cancer care?","Question",{"text":112,"@type":113},"The protocol addresses the need for accurate early prognostic assessment, since conventional clinicopathological methods may not reliably detect early recurrence risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which types of prognostic models are eligible for inclusion?",{"text":117,"@type":113},"Studies developing, validating, or evaluating biomarker-based, radiomics-based, and ML-guided prognostic models in human endometrial cancer patients are eligible, while purely laboratory biomarker discovery without a prognostic model in humans is excluded.",{"name":119,"@type":110,"acceptedAnswer":120},"How will prognostic performance and study quality be evaluated?",{"text":121,"@type":113},"Prognostic performance outcomes include AUC, C-index, time-dependent AUC, calibration metrics, hazard ratios, and decision analytic measures. Risk of bias will be assessed using PROBAST and QUIPS, with evidence certainty summarized using GRADE.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354758,1790183971,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Giri and Saroj Systematic Reviews (2026) 15:245 [https://doi.org/10.1186/s13643-026-03248-0](https://doi.org/10.1186/s13643-026-03248-0)  \nSystematic Reviews  \n SYSTEMATIC REVIEW Open Access  \nEarly risk prediction in endometrial cancer   using biomarker and machine learning models: a systematic review and meta-analysis protocol  \nPriya Giri1* and Rakesh Kumar Saroj1*  \nAbstract  \nBackground Globally, endometrial cancer (EC) is among the most prevalent gynaecological cancers, with rising incidence driven by demographic and metabolic changes. Accurate early prognostic assessment is essential to guide personalized treatment and improve long-term outcomes. Traditional clinicopathological prognostic methods-including FIGO (International Federation of Gynaecology and Obstetrics) staging, tumor grade, and histological subtype remain the current standard but have limitations in detecting early recurrence risk. In recent years, biomarker-based prognostic signatures and machine-learning (ML) guided risk models, including radiomics and multi-omics approaches, have emerged as promising tools for improving prognostic accuracy. However, no systematic review and meta-analysis have comprehensively evaluated whether these biomarker or ML-based prognostic models offer improved early risk prediction compared with conventional methods in EC.  \nMethods We will undertake a comprehensive search of MEDLINE, Scopus, IEEE Xplore, and Web of Science from 2010 to 2025. Two reviewers will independently perform title/abstract screening, full-text assessment, data extraction, and quality appraisal, with arbitration by a third reviewer where necessary. Studies developing, validating, or evaluating biomarker-based, radiomics-based and ML-guided prognostic models in human EC patients will be eligible for inclusion. Purely laboratory-based biomarker discovery studies that do not develop or evaluate a prognostic model in human participants will be excluded. Outcomes of interest include measures of prognostic performance such as AUC (area under the curve), C-index (concordance index), time-dependent AUC, calibration metrics, hazard ratios for survival outcomes, and decision analytic measures. Risk of bias will be assessed using PROBAST (Prediction model Risk of Bias Assessment Tool) and QUIPS (Quality in Prognosis Studies), and certainty of evidence will be summarized using GRADE (Grading of Recommendations Assessment, Development and Evaluation) . When feasible, meta-analysis of performance metrics will be performed using random-effects models with restricted maximum likelihood (REML) estimation, with subgroup analysis restricted to histological subtype when sufficient data permits. Discussion This systematic review will synthesize current evidence on the prognostic performance of biomarker and ML-guided prognostic models in EC, comparing them with conventional clinicopathological risk assessment methods. Findings will help clarify whether emerging model types offer meaningful improvements in the early prognostic accuracy, provide insight into methodological limitations of existing models, and identify gaps in evidence  \n*Correspondence: Priya Giri [priyag13_sit@jnu.ac.in](priyag13_sit@jnu.ac.in)[ ](priyag13_sit@jnu.ac.in)Rakesh Kumar Saroj [rakeshsaroj@jnu.ac.in](rakeshsaroj@jnu.ac.in)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are inc","cbCaioS19b1cW4zz","https://ap.wps.com/l/cbCaioS19b1cW4zz","pdf",939858,11,"English","# Abstract\n## Background\n## Methods\n## Discussion\n# Keywords\n# Background","[{\"question\":\"What problem does the review protocol address in endometrial cancer care?\",\"answer\":\"The protocol addresses the need for accurate early prognostic assessment, since conventional clinicopathological methods may not reliably detect early recurrence risk.\"},{\"question\":\"Which types of prognostic models are eligible for inclusion?\",\"answer\":\"Studies developing, validating, or evaluating biomarker-based, radiomics-based, and ML-guided prognostic models in human endometrial cancer patients are eligible, while purely laboratory biomarker discovery without a prognostic model in humans is excluded.\"},{\"question\":\"How will prognostic performance and study quality be evaluated?\",\"answer\":\"Prognostic performance outcomes include AUC, C-index, time-dependent AUC, calibration metrics, hazard ratios, and decision analytic measures. Risk of bias will be assessed using PROBAST and QUIPS, with evidence certainty summarized using GRADE.\"}]","Early risk prediction in endometrial cancer - using biomarker and machine learning models - a systematic review and meta-analysis protocol | PDF",1790113563,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7bddf2de3df57a83cd83797f3c590619.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21e31dc97df76b8266dba095c0655e7e.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3235e60f78b083b2086e8a67bfdf6686.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0728a86c2fb61d44842dfec95a06356.webp",980,1301]